Adalimumab, etanercept, infliximab and secukinumab data

OIA response

Request dated 6 May 2019 for data on etanercept, adalimumab, infliximab and secukinumab.

11 June 2019

[Name and contact details redacted]

Kia ora [Name redacted]


Thank you for your request dated 6 May 2019 under the Official Information Act 1982 (OIA). You asked for:

Data on etanercept, adalimumab, infliximab and secukinumab. You provided a template spreadsheet outlining the information you wanted.

Please find attached a spreadsheet (three worksheets) [XLSX, 26 KB] with the information you requested.

Individual patients cannot be identifiable in the data we release. Where a patient may be identified due to the rarity of the illness which means there are low patient numbers, the information provided has been stated as ‘0-10’. For your request, this applies to the data for pyoderma gangrenosum and adult-onset Still’s disease.

Accordingly, we have withheld a small amount of information from the spreadsheet as we consider this is necessary to protect the privacy of natural persons (section 9(2)(a) of the OIA).  

PHARMAC approaches its assessment of requests for information under the OIA on the basis that, once released, the information becomes publicly available - in other words once we release the information to you it becomes available to any other party in that exact form (whether by you distributing it to others or by virtue of us receiving the same request from a different third party).

As required under the OIA, we also considered whether, in the circumstances, the withholding of the information stated above was outweighed by other considerations which render it desirable, in the public interest, to make this information available.  In this case we did not consider that the public interest outweighed the reasons for withholding the information. 

Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.

We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website.  Please get in touch with us if you have any questions about this.

Yours sincerely

[Alison Hill's signature]

Alison Hill
Director, Engagement and Implementation